News

Saforis is an investigational therapy for the treatment and prevention of oral mucositis in patients receiving mucotoxic cancer therapy. The phase III trial of Saforis was conducted in

Barr anticipates receiving final approval following the expiration of Roche's patent in December 2007, or in June 2008 if Roche seeks and is granted pediatric exclusivity. Kytril is

The primary objective of the head-to-head trial is to compare the immune responses to two of the most common cancer causing strains of the human papillomavirus (HPV) in

GlaxoSmithKline has been awarded a contract for a value of at least $63.3 million. This contract is the latest to be awarded to the vaccine manufacturer and complements

The company said it intends to cooperate with the request. The subpoena seeks documents from 1999 to the present generally related to Endo’s knowledge of the use of

“This alliance is the fourth major partnership we have formed over the past six months and is consistent with our strategy to enable partners to leverage aptamers as

Topical ganciclovir has been available in Europe for the treatment of ocular viral infections for over 10 years. The product is currently marketed by Thea in Europe under

Xoma has received up-front payments for each of the additional collaboration programs and will also receive research funding for each project as well as success based milestones and

Geron scientists have described a newly discovered neurotrophic effect of the therapeutic GRNOPC1. In addition to the previously documented in vivo remyelinating activity of these cells, serves as